Inhibikase Therapeutics Inc —— 财务报表 (NASDAQ:IKT) | MetaTrader

展开完整图表

新闻

美银证券对Inhibikase股票启动覆盖并给予买入评级

BofA Securities initiates coverage on Inhibikase stock with Buy rating

Jefferies维持Inhibikase股票买入评级，引用FDA加速审批路径

Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path

H.C. Wainwright 开始对 Inhibikase 股票进行覆盖，给予买入评级

H.C. Wainwright assumes coverage on Inhibikase stock with Buy rating

Monday’s Insider Activity: Top Executives Trade Shares at Tech Giants

Why Intuit Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Gap (NYSE:GAP), Elastic (NYSE:ESTC)

Inhibikase Therapeutics定价1亿美元公开发行

Inhibikase Therapeutics prices $100 million public offering

Inhibikase Therapeutics股价在宣布公开发行后下跌

Inhibikase Therapeutics stock falls after announcing public offering